ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS

ENHERTU demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of...

Related Keywords

Japan , Cambridge , Cambridgeshire , United Kingdom , Canada , Jerusalem , Israel General , Israel , Daiichi Sankyo , Trastuzumab Deruxtecan , Capecitabine Monotherapy , End Results Program , Merck Co Inc , National Cancer Institute , Astrazeneca , Daiichi Sankyo Inc , Low Metastatic Breast Cancer , Solid Tumors , Positive Locally Advanced , Metastatic Gastric Cancer , Positive Metastatic Breast , Low Metastatic Breast , Mutant Unresectable , Metastatic Solid , Reproductive Potential , Hepatic Impairment , Prescribing Information , Rare Diseases , Cancer Res , Plus Exemestane , Oestrogen Receptor , Negative Advanced Breast , End Results , Accessed April , Epidermal Growth Factor Receptor , Mol Biol , Pathol Transl , Previously Treated , Low Advanced Breast , Markets ,